Uptake of cardiac screening and genetic testing among hypertrophic and dilated cardiomyopathy families

Erin M. Miller, Yu Wang, Stephanie Ware

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Cardiomyopathy is a genetically and clinically heterogeneous, life threatening disease which affects people of all ages. Recent guidelines provide recommendations for cardiac screening and genetic testing in at-risk relatives, but the uptake and impact of these measures in the United States is unknown. This is a single institution retrospective study that characterizes the uptake of cardiac screening and genetic testing for relatives of a cohort of 57 probands with hypertrophic (HCM) and dilated cardiomyopathy (DCM) who underwent both clinical evaluation and genetic testing. Cardiac screening was indicated for 302 relatives. One hundred and seventy-three (57 %) completed cardiac screening. Forty of the 57 probands were mutation positive and genetic testing was indicated for 213 relatives. Eighty-four (39 %) completed genetic testing. The uptake of cardiac surveillance was greater than the uptake of genetic testing (p <0.0001) among relatives of mutation positive probands. Within the group of at-risk, asymptomatic relatives of probands, cardiac screening and genetic testing were positive in 25 % and 40 % of cases, respectively. These data demonstrate the important role and utility of cascade cardiac screening and genetic testing in the care of patients and families with HCM or DCM. The approach to cardiac screening and genetic testing should be family-specific and requires expertise in the genetics of cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)258-267
Number of pages10
JournalJournal of Genetic Counseling
Volume22
Issue number2
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Hypertrophic Cardiomyopathy
Dilated Cardiomyopathy
Genetic Testing
Cardiomyopathies
Mutation
Patient Care
Retrospective Studies
Guidelines

Keywords

  • Familial dilated cardiomyopathy
  • Familial hypertrophic cardiomyopathy
  • Genetic counseling
  • Predictive genetic testing

ASJC Scopus subject areas

  • Genetics(clinical)
  • Medicine(all)

Cite this

Uptake of cardiac screening and genetic testing among hypertrophic and dilated cardiomyopathy families. / Miller, Erin M.; Wang, Yu; Ware, Stephanie.

In: Journal of Genetic Counseling, Vol. 22, No. 2, 04.2013, p. 258-267.

Research output: Contribution to journalArticle

@article{e146e1f45c3742ec98086f4bc25809d1,
title = "Uptake of cardiac screening and genetic testing among hypertrophic and dilated cardiomyopathy families",
abstract = "Cardiomyopathy is a genetically and clinically heterogeneous, life threatening disease which affects people of all ages. Recent guidelines provide recommendations for cardiac screening and genetic testing in at-risk relatives, but the uptake and impact of these measures in the United States is unknown. This is a single institution retrospective study that characterizes the uptake of cardiac screening and genetic testing for relatives of a cohort of 57 probands with hypertrophic (HCM) and dilated cardiomyopathy (DCM) who underwent both clinical evaluation and genetic testing. Cardiac screening was indicated for 302 relatives. One hundred and seventy-three (57 {\%}) completed cardiac screening. Forty of the 57 probands were mutation positive and genetic testing was indicated for 213 relatives. Eighty-four (39 {\%}) completed genetic testing. The uptake of cardiac surveillance was greater than the uptake of genetic testing (p <0.0001) among relatives of mutation positive probands. Within the group of at-risk, asymptomatic relatives of probands, cardiac screening and genetic testing were positive in 25 {\%} and 40 {\%} of cases, respectively. These data demonstrate the important role and utility of cascade cardiac screening and genetic testing in the care of patients and families with HCM or DCM. The approach to cardiac screening and genetic testing should be family-specific and requires expertise in the genetics of cardiomyopathy.",
keywords = "Familial dilated cardiomyopathy, Familial hypertrophic cardiomyopathy, Genetic counseling, Predictive genetic testing",
author = "Miller, {Erin M.} and Yu Wang and Stephanie Ware",
year = "2013",
month = "4",
doi = "10.1007/s10897-012-9544-4",
language = "English (US)",
volume = "22",
pages = "258--267",
journal = "Journal of Genetic Counseling",
issn = "1059-7700",
publisher = "Kluwer Academic/Human Sciences Press Inc.",
number = "2",

}

TY - JOUR

T1 - Uptake of cardiac screening and genetic testing among hypertrophic and dilated cardiomyopathy families

AU - Miller, Erin M.

AU - Wang, Yu

AU - Ware, Stephanie

PY - 2013/4

Y1 - 2013/4

N2 - Cardiomyopathy is a genetically and clinically heterogeneous, life threatening disease which affects people of all ages. Recent guidelines provide recommendations for cardiac screening and genetic testing in at-risk relatives, but the uptake and impact of these measures in the United States is unknown. This is a single institution retrospective study that characterizes the uptake of cardiac screening and genetic testing for relatives of a cohort of 57 probands with hypertrophic (HCM) and dilated cardiomyopathy (DCM) who underwent both clinical evaluation and genetic testing. Cardiac screening was indicated for 302 relatives. One hundred and seventy-three (57 %) completed cardiac screening. Forty of the 57 probands were mutation positive and genetic testing was indicated for 213 relatives. Eighty-four (39 %) completed genetic testing. The uptake of cardiac surveillance was greater than the uptake of genetic testing (p <0.0001) among relatives of mutation positive probands. Within the group of at-risk, asymptomatic relatives of probands, cardiac screening and genetic testing were positive in 25 % and 40 % of cases, respectively. These data demonstrate the important role and utility of cascade cardiac screening and genetic testing in the care of patients and families with HCM or DCM. The approach to cardiac screening and genetic testing should be family-specific and requires expertise in the genetics of cardiomyopathy.

AB - Cardiomyopathy is a genetically and clinically heterogeneous, life threatening disease which affects people of all ages. Recent guidelines provide recommendations for cardiac screening and genetic testing in at-risk relatives, but the uptake and impact of these measures in the United States is unknown. This is a single institution retrospective study that characterizes the uptake of cardiac screening and genetic testing for relatives of a cohort of 57 probands with hypertrophic (HCM) and dilated cardiomyopathy (DCM) who underwent both clinical evaluation and genetic testing. Cardiac screening was indicated for 302 relatives. One hundred and seventy-three (57 %) completed cardiac screening. Forty of the 57 probands were mutation positive and genetic testing was indicated for 213 relatives. Eighty-four (39 %) completed genetic testing. The uptake of cardiac surveillance was greater than the uptake of genetic testing (p <0.0001) among relatives of mutation positive probands. Within the group of at-risk, asymptomatic relatives of probands, cardiac screening and genetic testing were positive in 25 % and 40 % of cases, respectively. These data demonstrate the important role and utility of cascade cardiac screening and genetic testing in the care of patients and families with HCM or DCM. The approach to cardiac screening and genetic testing should be family-specific and requires expertise in the genetics of cardiomyopathy.

KW - Familial dilated cardiomyopathy

KW - Familial hypertrophic cardiomyopathy

KW - Genetic counseling

KW - Predictive genetic testing

UR - http://www.scopus.com/inward/record.url?scp=84879688303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879688303&partnerID=8YFLogxK

U2 - 10.1007/s10897-012-9544-4

DO - 10.1007/s10897-012-9544-4

M3 - Article

VL - 22

SP - 258

EP - 267

JO - Journal of Genetic Counseling

JF - Journal of Genetic Counseling

SN - 1059-7700

IS - 2

ER -